Enzyme News and Research

RSS

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Ahead of World Malaria Day (25 April), EU-funded researchers have discovered that drugs originally designed to inhibit the growth of cancer cells can also kill the parasite that causes malaria. They believe this discovery could open up a new strategy for combating this deadly disease, which, according to World Health Organisation statistics, infected around 225 million and killed nearly 800 000 people worldwide in 2009.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Penn researchers explore the role of telomere caps in human aging

Researchers at the University of Pennsylvania School of Medicine are delving into the details of the complex structure at the ends of chromosomes.

21 Apr 2011

New trial in UK to test whether statins could be used to treat pre-eclampsia

Pregnant women could benefit from a pioneering trial that will test whether heart disease drugs can be used to treat pre-eclampsia.

21 Apr 2011

Genetically modified mosquitoes tested to prevent spread of malaria: Study

According to the latest study in the journal Nature, researchers from Imperial College London and the University of Washington, Seattle found that after making specific genetic changes to a few mosquitoes and then allowing them to breed could eventually dramatically reduce the spread of the deadly disease malaria.

20 Apr 2011

Combination therapy restores skilled use of limb in rodent model

After the acute treatment window closes, the only effective treatment for stroke is physical/occupational therapy. Now scientists from Children's Hospital Boston report a two-pronged molecular therapy that leads to significant recovery of skilled motor function in a rat model of stroke.

20 Apr 2011

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.

20 Apr 2011

Adamis acquires cancer vaccine technology from UCSD

Adamis Pharmaceuticals Corporation (OTCBB: ADMP) today announced the completion of the acquisition of a unique patented cancer vaccine technology from the Regents of the University of California.

20 Apr 2011

Single antibody injection limits tissue and organ destruction after ischaemic events

Medical researchers today held out promise that a simple injection is being developed to limit the devastating consequences of heart attacks and strokes.

19 Apr 2011

Non-alcoholic fatty liver disease linked to coronary artery disease

Because of the prevalence of obesity in our country, many Americans are expected to develop a serious condition called non-alcoholic fatty liver disease (NAFLD), which can lead to cirrhosis, fibrosis, and in some cases liver failure. It is also one of the best predictors for coronary artery disease.

18 Apr 2011

Scientists identify networks of genes critical in embryonic-heart development

Scientists at the Gladstone Institutes have identified networks of genes that play an important role in embryonic-heart development, advancing knowledge of how healthy hearts develop-and offering clues about how to combat a common birth defect known as congenital heart disease.

18 Apr 2011

Eli Lilly receives FDA complete response letter for liprotamase NDA

Eli Lilly and Company has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for liprotamase, a non-porcine pancreatic enzyme replacement therapy, under investigation for the treatment of exocrine pancreatic insufficiency.

16 Apr 2011

Chronic exposure to polluted air can lead to inflammation

Chronic inhalation of polluted air appears to activate a protein that triggers the release of white blood cells, setting off events that lead to widespread inflammation, according to new research in an animal model.

16 Apr 2011

FEN1 enzyme might serve as anti-cancer therapy target

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.

15 Apr 2011

Investigational Alzheimer's compounds may treat neuropathies

Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis.

15 Apr 2011

Halozyme announces Aspart-PH20 study results in type 1 diabetes

Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.

15 Apr 2011

Researchers report injectable gel can help treat arthritis

Some 25 million people in the United States alone suffer from rheumatoid arthritis or its cousin osteoarthritis, diseases characterized by often debilitating pain in the joints. Now researchers at Brigham and Women's Hospital report an injectable gel that could spell the future for treating these diseases and others.

15 Apr 2011

Researchers show how TET1 enzyme controls fetal development and fights cancer

To ensure normal fetal development and prevent disease, it is crucial that certain genes are on or off in the right time intervals. Researchers in Professor Kristian Helin's group at BRIC, University of Copenhagen, have now shown how the TET1 enzyme controls the activity of our genes. The results are just published in the journal Nature.

15 Apr 2011

Consumer group calls for ban on weight loss drugs Alli and Xenical

According to the consumer watchdog Public Citizen, the weight loss drugs Alli and Xenical should be removed from the market because of the growing risk of side effects that include liver damage, pancreatitis and kidney stones.

15 Apr 2011

Medicinal applications of fullerenes, filled with radioactive material

Fullerenes have attracted considerable attention in different fields of science since their discovery in 1985. Investigations of physical, chemical and biological properties of fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-dimensionality and electronic configurations make them an appealing subject in medicinal chemistry. Their unique carbon cage structure coupled with immense scope for derivatization make them a potential therapeutic agent.

13 Apr 2011